- Home
- ARQ vs IPHA Comparison
ARQ vs IPHA Comparison
Compare ARQ & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQ
- IPHA
- Stock Information
- Founded
- ARQ 1996
- IPHA 1999
- Country
- ARQ United States
- IPHA France
- Employees
- ARQ N/A
- IPHA N/A
- Industry
- ARQ
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- ARQ
- IPHA Health Care
- Exchange
- ARQ NYSE
- IPHA Nasdaq
- Market Cap
- ARQ 175.6M
- IPHA 160.1M
- IPO Year
- ARQ N/A
- IPHA 2019
- Fundamental
- Price
- ARQ $3.98
- IPHA $1.97
- Analyst Decision
- ARQ Strong Buy
- IPHA Strong Buy
- Analyst Count
- ARQ 1
- IPHA 1
- Target Price
- ARQ $9.00
- IPHA $11.50
- AVG Volume (30 Days)
- ARQ 332.6K
- IPHA 16.1K
- Earning Date
- ARQ 03-05-2025
- IPHA 03-27-2025
- Dividend Yield
- ARQ N/A
- IPHA N/A
- EPS Growth
- ARQ N/A
- IPHA N/A
- EPS
- ARQ N/A
- IPHA N/A
- Revenue
- ARQ $108,959,000.00
- IPHA $20,831,349.00
- Revenue This Year
- ARQ $32.45
- IPHA $220.44
- Revenue Next Year
- ARQ $16.18
- IPHA $81.85
- P/E Ratio
- ARQ N/A
- IPHA N/A
- Revenue Growth
- ARQ 9.86
- IPHA N/A
- 52 Week Low
- ARQ $4.01
- IPHA $1.29
- 52 Week High
- ARQ $8.26
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- ARQ 25.94
- IPHA 49.68
- Support Level
- ARQ $4.04
- IPHA $1.76
- Resistance Level
- ARQ $4.33
- IPHA $2.21
- Average True Range (ATR)
- ARQ 0.22
- IPHA 0.12
- MACD
- ARQ -0.02
- IPHA -0.01
- Stochastic Oscillator
- ARQ 3.30
- IPHA 44.67
Stock Price Comparison Chart: ARQ vs IPHA
About ARQ ARQ INC
Arq Inc is an environmental technology company principally engaged in the sale of consumable air, water, and soil treatment solutions including activated carbon (AC) and chemical technologies. The company manufactures and sells activated carbon and other chemicals used to capture and remove contaminants for the coal-fired power generation, industrial, municipal water and air, water and soil treatment and remediation markets. Some of the products in its portfolio are Powdered Activated Carbon, Granula Activated Carbon, and Colloidal Carbon Product among others.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.